Ischemic placental disease: A unifying concept for preeclampsia, intrauterine growth restriction, and placental abruption

Seminars in Perinatology

Volumn 38, Issue 3, 2014, Pages 131-132

  Ananth, Cande V ^a,b  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^b Mailman School of Public Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; BLOOD CLOTTING DISORDER; EDITORIAL; EXTRACELLULAR MATRIX; HUMAN; INFECTION; INFLAMMATION; INTRAUTERINE GROWTH RETARDATION; ISCHEMIC PLACENTAL DISEASE; PATHOPHYSIOLOGY; PERINATAL MORBIDITY; PERINATAL MORTALITY; PLACENTA DISORDER; PREECLAMPSIA; PRIORITY JOURNAL; RISK FACTOR; SOLUTIO PLACENTAE; THROMBOSIS; ABRUPTIO PLACENTAE; COMPLICATION; FEMALE; FETAL GROWTH RETARDATION; ISCHEMIA; PATHOLOGY; PRE-ECLAMPSIA; PREGNANCY;

ABRUPTIO PLACENTAE; FEMALE; FETAL GROWTH RETARDATION; HUMANS; ISCHEMIA; PRE-ECLAMPSIA; PREGNANCY; RISK FACTORS;

EID: 84900440222     PISSN: 01460005     EISSN: 1558075X     Source Type: Journal    
DOI: 10.1053/j.semperi.2014.03.001     Document Type: Editorial

References (15)

1. Ananth C.V., Vintzileos A.M. Maternal-fetal conditions necessitating a medical intervention resulting in preterm birth. Am J Obstet Gynecol 2006, 195:1557-1563.
2. Srinivas S.K., Edlow A.G., Neff P.M., Sammel M.D., Andrela C.M., Elovitz M.A. Rethinking IUGR in preeclampsia: dependent or independent of maternal hypertension?. J Perinatol 2009, 29:680-684.
3. Karumanchi S.A., Lindheimer M.D. Advances in the understanding of eclampsia. Curr Hypertens Rep 2008, 10:305-312.
4. Redman C.W., Sargent I.L. Latest advances in understanding preeclampsia. Science 2005, 308:1592-1594.
5. Redman C.W., Sargent I.L. Placental stress and pre-eclampsia: a revised view. Placenta 2009, 30(suppl A):S38-S42.
6. Roberts J.M., Cooper D.W. Pathogenesis and genetics of pre-eclampsia. Lancet 2001, 357:53-56.
7. Sibai B.M. Maternal and uteroplacental hemodynamics for the classification and prediction of preeclampsia. Hypertension 2008, 52:805-806.
8. Christianson R.E. Gross differences observed in the placentas of smokers and nonsmokers. Am J Epidemiol 1979, 110:178-187.
9. Signore C., Mills J.L., Qian C., Yu K.F., Rana S., Karumanchi S.A., et al. Circulating soluble endoglin and placental abruption. Prenat Diagn 2008, 28:852-858.
10. Ness R.B., Roberts J.M. Heterogeneous causes constituting the single syndrome of preeclampsia: a hypothesis and its implications. Am J Obstet Gynecol 1996, 175:1365-1370.
11. Ness R.B., Sibai B.M. Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. Am J Obstet Gynecol 2006, 195:40-49.
12. Villar J., Carroli G., Wojdyla D., Abalos E., Giordano D., Ba'aqeel H., et al. Preeclampsia, gestational hypertension and intrauterine growth restriction, related or independent conditions?. Am J Obstet Gynecol 2006, 194:921-931.
13. Ananth C.V., Smulian J.C., Vintzileos A.M. Ischemic placental disease: maternal versus fetal clinical presentations by gestational age. J Matern Fetal Neonatal Med 2010, 23:887-893.
14. Ananth C.V., Vintzileos A.M. Medically indicated preterm birth: recognizing the importance of the problem. Clin Perinatol 2008, 35:53-67.
15. Ananth C.V., Kinzler W.L. Placental Abruption: Clinical Features and Diagnosis 2014, UpToDate, Wolters Kluwer Health, Philadelphia, PA. http://www.uptodate.com/contents/placental-abruption-clinical-features-and-diagnosis.